For the Scientific Community

The goal of the Biobank PROCURE is to provide researchers with biospecimens and data of the highest quality, with a view to advancing prostate cancer research and improving the quality of care provided to men affected by this cancer. All spheres of biomedical research will benefit, wether for the identification of biomarkers in the blood, urine or tumors themselves, the identification of genetic, environmental and other risk factors, or for the development of targeted treatments.

Scope of research

Regarding the scope of these research, we can think of the stratification of patient populations, the prediction of the aggressiveness and evolution of this cancer, the ability of cancer cells to resist, grow and spread in the body, etc.In addition, socio-demographic data collected in pre-surgery and five or six years post-surgery in nearly 2,000 participants, in combination with biological and clinico-pathological data, can constitute an immense database and thus generate numerous studies of great value. These studies, in turn, will have major consequences for the advancement of basic, translational and clinical research, towards a precision medicine.

One of a kind

The PROCURE Biobank is unique by:

  • The harmonization of procedures (SOP) through the 4 collection sites.
  • The characterization of fixed and frozen tissues by pathologists of the Biobank.
  • The character of the cohort, which is predominantly Canadian and French-speaking.
  • The cohort study is a longitudinal type cohort.
  • The collection of biospecimens (blood and urine) and clinico-pathological data that are updated during all medical visits.
  • The socio-demographic data collection that took place at the prostatectomy.

International recognition

All together, with an ambitious and motivated team animated by a spirit of wanting to make a REAL a difference in the lives of men with prostate cancer, we have continuously evolved and soared to new heights.
Today, 10 years later, the PROCURE Biobank is praised worldwide by researchers and specialists in the prostate cancer field for the high quality and scientific value of its material, is certified by the Canadian Tissue Repository Network – a consortium which brings together state-of-the-art provincial banks and programs ( – and is listed in the Global Biobanks Directory. Something to be proud of!



Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: methods, validation, and impact on the pathological prognostic parameters in radical prostatectomy. Brimo F, Sircar K, Chevalier S, Saad F, Lacombe L, Têtu B, Scarlata E, Aprikian A.Cell Tissue Bank. 2012 Dec;13(4):631-8.

Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank. Brimo F, Aprikian A, Latour M, Têtu B, Doueik A, Scarlata E, Hamel L, McKercher G, Saad F, Lacombe L, Carmel M, Chevalier S.Biopreserv Biobank. 2013 Oct;11(5):285-90.

A Simple Variable Number of Tandem Repeat-Based Genotyping Strategy for the Detection of Handling Errors and Validation of Sample Identity in Biobanks. Pellerin C, McKercher G, Aprikian AG, Saad F, Lacombe L, Carmel M, Chevalier S.Biopreserv Biobank. BJU Int. 2018 Aug 16. doi: 10.1111/bju.14512. [Epub ahead of print].

Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.
Wissing M, Brimo F, Chevalier S, Scarlata E, McKercher G, O’Flaherty A, Aprikian S, Thibodeau V, Saad F, Carmel M, Lacombe L, Têtu B, Ekindi-Ndongo N, Latour M, Trudel D, Aprikian A. 2018 Oct;14(5):383-389.

The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer.
Wissing M1,2, Chevalier S3,4, McKercher G3,4,5, Laprise C6, Aprikian S4,5, O’Flaherty A3, Scarlata E3,4, Saad F7, Carmel M8, Lacombe L9, Brimo F10, Latour M11, Ekindi-Ndongo N12, Têtu B13, Aprikian A3,6,4 World J Urol. 2018 Aug 22. doi: 10.1007/s00345-018-2457-6.


Summary: In the United States, The Cancer Genome Atlas (NIH) was a major project aimed at the integral molecular characterization of the prostate cancer genome using 333 frozen prostate tissue samples including 22 from the PROCURE Biobank cohort. This research revealed seven new subtypes of prostate cancer. These subtypes may have implications for improving prognosis and treatment.

The Molecular Taxonomy of Primary Prostate Cancer. Cancer Genome Atlas Research Network.Cell.2015 Nov 5;163(04):1011.

Summary: In Quebec, the FRQ-S innovant project focuses on the discovery of new biomarkers of recurrence and on the risks of progression of prostate cancer by studying the androgen production / inhibition pathway. This project uses plasma, DNA and urine from the full cohort of the PROCURE Biobank.

The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. Belledant, H. Hovington, L. Garcia, P. Caron, H. Brisson, L. Villeneuve, D. Simonyan, B. Têtu, Y. Fradet,L. Lacombe, C. Guillemette, É. Lévesque; European Urology 68(4):601-609, 2016.